prevacid on sale
DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 21, 2004--Elan Corporation, plc today announced four transactions collectively representing additional proceeds of approximately $70 million. The transactions are:The sale of the company's San Diego office property and the completion of a multi-year rental agreement with the new ownerThe sale, subject to certain closing conditions, of Elan Pharma S. A., a manufacturing and research and development business based in Mezzovico, Switzerland, to affiliates of a U. S.investment banking firm, Sanders Morris Harris, together with the associated fast-melt and effervescent intellectual propertyThe sale of the company's Segix Italia manufacturing business, based in Pomezia, Italy, to a management buyout teamThe receipt of a $25 million milestone payment, pursuant to a previously announced term of the amended transaction agreement between Elan and King Pharmaceuticals, Inc.that was contingent upon ongoing patent exclusivity for Skelaxin(TM) (metaxalone). Elan President and CEO Kelly Martin said, "These transactions are consistent with our strategy of focusing our resources on our core therapeutic focus areas, developing our pipeline, and bringing innovative science to patients. prevacid zantac different milligrams of prevacid 2737 aid prevacid viagra zyrtec pneumonia prevacid